Extracorporeal high-intensity focused ultrasound for VX2 liver tumors in the rabbit

Prat, Frédéric; Centarti, Maria; Sibille, Alain; Fadil, Fatima Abou El; Henry, Luc; Chapelon, Jean‐Yves; Cathignol, D.

doi:10.1002/hep.1840210333

Cited by 40 publications

(29 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The energy deposition of focused US on the target tissue causes coagulative necrosis of tumours (Chapelon et al, 1992;Chen et al, 1993;Sibille et al, 1993;Prat et al, 1995;Rowland et al, 1997). In this study, pathological examination revealed that both breast cancer cells and normal tissues within the treated region presented a typical appearance of coagulative necrosis with severe nuclear damage.…”

Section: Discussionmentioning

confidence: 64%

“…These advantages make it one of the most attractive potential therapies for the localised treatment of tumour. To our knowledge, most of the studies on HIFU have been dealing with animal experiments in which HIFU has induced target lesions at depth in tumour tissues and normal organs, including liver, kidney, prostate, bladder, and soft tissue (Chapelon et al, 1992;Chen et al, 1993;Sibille et al, 1993;Prat et al, 1995;Rowland et al, 1997).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer

et al. 2003

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) is a noninvasive treatment that induces complete coagulative necrosis of a tumour at depth through the intact skin. This study was to explore the possibility of using HIFU for the treatment of patients with localised breast cancer in a controlled clinical trial. A total of 48 women with biopsy-proven breast cancer (T 1 -2 , N 0 -2 , M 0 ) were randomised to the control group in which modified radical mastectomy was performed, and the HIFU group in which an extracorporeal HIFU ablation of breast cancer was followed by modified radical mastectomy. Short-term follow-up, pathologic and immunohistochemical stains were performed to assess the therapeutic effects on tumour and complications of HIFU. The results showed that no severe side effect was observed in the HIFU-treated patients. Pathologic findings revealed that HIFU-treated tumour cells underwent complete coagulative necrosis, and tumour vascular vessels were severely damaged. Immunohistochemical staining showed that no expression of PCNA, MMP-9, and CD44v6 was detected within the treated tumour cells in the HIFU group, indicating that the treated tumour cells lost the abilities of proliferation, invasion, and metastasis. It is concluded that, as a noninvasive therapy, HIFU could be effective, safe, and feasible in the extracorporeal treatment of localised breast cancer.

show abstract

Section: Discussionmentioning

confidence: 64%

mentioning

confidence: 99%

A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer

et al. 2003

View full text Add to dashboard Cite

show abstract

“…114 The use of local irradiation using 90 yttrium seed implants has also been reported. 115 Intratumoral ethanol injection, a therapy that has gained wide acceptance for unresectable hepatocellular cancer, 116 is less effective in ethanol metastatic lesions, which are denser and result in with less capacity for diffusion.…”

Section: Cryosurgery and Other Forms Of Local Hepatic Ablative Therapymentioning

confidence: 99%

Management of hepatic metastases

Choti

Bulkley

1999

Liver Transpl

View full text Add to dashboard Cite

Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms. Copyright 1999 by the American Association for the Study of Liver DiseasesA s many as 50% of the patients with a primary malignancy will eventually develop metastases in the liver, a percentage greater than for any other organ, including the lung. Although primary tumors that drain principally into the portal circulation are more likely than others to develop hepatic metastases, many tumors arising in other sites, such as the breast and lung, also commonly develop hepatic metastases. Although the liver represents a common site of spread from many of these solid tumors, isolated hepatic metastases most commonly occur from colorectal and neuroendocrine tumors. Other less common malignancies also can metastasize predominantly to the liver. For most other solid malignancies, the pattern of metastatic disease is most often that of generalized dissemination. Colorectal MetastasesCancer of the colon and rectum is the third most commonly diagnosed cancer in the United States. An estimated 131,600 new cases will have been discovered in 1998, comprising 11% of new cancer diagnoses. 1 An estimated 56,500 deaths will occur from colorectal cancer that year, comprising 10% of all cancer deaths. 1 Although mortality from largebowel cancer has been improving over the past 30 years, largely because of improvements in early detection, diagnosis, and treatment, approximately 50% of the patients with colorectal cancer eventually die of their neoplastic disease. 1 The liver is the most commonly involved organ in patients with metastatic colorectal cancer. Approximately 20% of these patients have clinically recognizable liver metastases at the time of their primary diagnosis. 1,2 After resection of a primary colorectal cancer in the absence of apparent metastatic disease, approximately 50% of the patients will subsequently manifest metastatic liver disease. Given these figures,...

show abstract

“…HIFU techniques for solid tumors treatment have been reported as noninvasive and conformal with real-time monitoring [10,11] . In animal experiments and clinical studies, it has been proven that HIFU can selectively target and destroy primary or metastatic lesions through intake skin, thereby treating tumors in the liver [10,12,13] or other solid organs such as kidney [14][15][16] , bone [17] , prostate [18][19][20] , pancreas [21] , etc. Although HIFU treatment for recurrent and metastatic abdominal tumors was generally thought to be noninvasive and safe, we observed some common and even severe complications in our practice, and the aim of this study was to analyze the local and systemic complications of HIFU in patients with recurrent and metastatic abdominal tumors.…”

Section: Introductionmentioning

confidence: 99%

Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors

Xu²,

Gu³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To analyze the local and systemic complications of high intensity focused ultrasound (HIFU) for patients with recurrent and metastatic abdominal tumors. METHODS:From Aug 2001 to Aug 2004, 17 patients with recurrent and metastatic abdominal tumors were enrolled in this study. Real-time sonography was taken, and vital signs, liver and kidney function, skin burns, local reactions, and systemic effects were observed and recored before, during, and after HIFU. CT and MRI were also taken before and after HIFU. RESULTS:All 17 patients had skin burns and pain in the treatment region; the next common complication was neurapraxia of the stomach and intestines to variable degrees. The other local and systemic complications were relatively rare. Severe complications were present in two patients; one developed a superior mesenteric artery infarction resulting in necrosis of the entire small intestines, and the other one suffered from a perforation in terminal ileum due to HIFU treatment. CONCLUSION:Although HIFU is a one of noninvasive treatments for the recurrent and metastatic abdominal tumors, there are still some common and severe complications which need serious consideration.

show abstract

Extracorporeal high-intensity focused ultrasound for VX2 liver tumors in the rabbit

Cited by 40 publications

References 14 publications

A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer

A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer

Management of hepatic metastases

Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors

Contact Info

Product

Resources

About